Background. The presence of a 2 -macroglobulin (a 2 M) in amyloid tissue from patients with dialysis-related amyloidosis (DRA) was demonstrated by Argilés et al in 1989. Thereafter, the formation of the complex of b 2 -microglobulin (b 2 m) with a 2 m was confirmed directly by in vitro study. In Alzheimer's disease, complex formation of amyloid b-peptide and a 2 M is considered to play an important role in the pathogenesis by modifying the degradation processes of amyloid protein. Thus, we hypothesized that the a 2 M-b 2 m complex is an important factor in the pathogenesis of DRA as well. Here, we measured the circulating levels of a 2 M-b 2 m complex in the maintenance hemodialysis patients and discussed about its clinical significance in DRA.
a 2 -macroglobulin (a 2 M) is a major protease inhibitor in vivo [1, 2] . So far, several reports have been published suggesting the presence of protease inhibitors such as a 2 M and a 1 antichymotripsin in amyloid fibrils from Alzheimer's disease or dialysis-related amyloidosis (DRA) patients [3] [4] [5] [6] . More recently, the very potent inhibitory action of a 2 M on proteases has been interpreted as being indicative of an involvement of a 2 M in amyloidrelated protein metabolism. In consequence of this, it has been hypothesized that a 2 M may modify the degradation processes of amyloid proteins and may play an active role in the pathogenesis of amyloidosis.
In Alzheimer's disease, amyloid b peptide, a precursor protein of the disease, has now been corroborated to form a complex with a 2 M in in vitro studies [7, 8] .
Subsequently, b 2 -microglobulin (b 2 m), a precursor protein of DRA, has been reported to form a complex with a 2 M [9] . On the basis of this evidence, the "a 2 M hypothesis" has been forwarded by Argilés et al [10] as an interesting mechanism to account for the pathogenesis of DRA. Based on this complex-mediated promotion concept, we established an assay system using the enzyme immunoassay method for a 2 M-b 2 m complex and measured its serum level in 137 hemodialysis patients as well as 11 prehemodialysis patients.
METHODS

Subjects
One hundred and thirty-seven hemodialysis patients, 11 prehemodialysis patients with chronic renal failure (CRF) (control subjects, prehemodialysis CRF patients), and 15 normal persons were enrolled in this study after obtaining their oral consent.
All patients were nondiabetic. Their average ages were 58 years in the hemodialysis patients, 61 years in the control subjects, and 33 years in the normal persons. Gender breakdown was 77 males and 60 females of the hemodialysis patients, nine males and two females of the prehemodialysis CRF patients, and 12 males and three females of normal persons. Duration of hemodialysis varied from 2 to 290 months, 123 months in average. All hemodialysis patients underwent hemodialysis or hemodiafiltration with bicarbonate dialysate twice or three times a week. Several kinds of dialyzers were used at the time of the study, including polysulfone (N = 45), polyacrylonitrile (N = 36), ethylenevinylalcohol (N = 31), cellulose triacetate (N = 20), and others (N = 5).
The clinical diagnosis of DRA was evaluated as previously reported [11] . In brief, all clinical signs were scored by the criteria of Gejyo et al [12] , which ranks the clinical features of DRA from 0 to 7 according to joint pain, bone cyst on x-ray film, and carpal tunnel syndrome. The DRA scores were negative in 84 cases (0 in 58 cases, 1 in 26 cases), mild in 33 cases (2 in 21 cases, 3 in 12 cases), and high in 20 cases (4 in ten cases, 5 in five cases, 6 in three cases, and 7 in two cases).
The operation for carpal tunnel syndrome had been done in 20 patients, the amyloid bone cyst in either carpal, shoulder, or hip bone was confirmed in 70 patients and 47 patients showed symptoms of multiple joint pain. Eleven patients who had a moderate or high DRA score had been undergoing hemodiafiltration for 6 months or more.
As far as we could survey, there were no reports concerning the complex of a 2 M-b 2 m even in the patients with the systemic AA amyloidosis. Therefore, age-matched prehemodialysis CRF patients served as control in this study.
Laboratory characteristics
Serum creatinine values were 12.0 ± 0.3 mg/dL in the hemodialysis patients and 5.4 ± 2.3 mg/dL in the prehemodialysis CRF patients. Serum values of b 2 m were 35.7 ± 8.5 mg/L in the hemodialysis patients and 10.7 ± 6.0 mg/L in the prehemodialysis CRF patients. Values of serum total protein, albumin, C-reactive protein, and concentration of hemoglobin were 6.5 ± 0.4 g/dL, 3.8 ± 0.3 g/dL, 0.24 ± 0.31 mg/dL, and 10.0 ± 1.2 g/dL, respectively, in hemodialysis patients. All data in hemodialysis patients were values before hemodialysis.
Measurement of a circulating a 2 M-b 2 m complex
The affinity of b 2 m for a 2 M. The affinity of b 2 m for a 2 M was examined by using a highly sensitive 27 MHz quartz crystal microbalance (QCM) (Affinix Q) (Inishi- amu Co., Tokyo, Japan) as described earlier [13, 14] . Briefly, 2 lL of 200 lg/mL a 2 M was directly immobilized on a QCM plate, and the plate was soaked in 6 mL of 10% dimethyl sulfoxide (DMSO) at 25 • C. The resonance frequency of the QCM was defined as the 0 position after equilibrium. The stability and drift of the 27 MHz QCM frequency in the solution were ± 5 Hz for 12 hours at 25 • C. Preparation of standard a 2 M-b 2 m complex. A a 2 Mb 2 m complex was prepared as described previously [9] . Other chemicals were of analytic grade. In outline, 1 mL of 0.1 mg/mL b 2 m (Sigma Chemical Co., St. Louis, MO, USA) was incubated with 1 mL of 1 mg/mL a 2 M (Sigma Chemical Co.) for 36 hours in 66.6 mmol/L phosphate buffer at room temperature. Specificity of the standard complex was studied by Western blotting as shown in Figure 1 . The complex was used as a sample for Western blotting or a standard for enzyme immunoassay.
Western blotting. Prepared a 2 M-b 2 m complex, commercial b 2 m, and commercial a 2 M were run by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at 18 mA for 1 1 / 2 hours with a 4% to 20% gradient gel (Tefco, Tokyo, Japan). Prepared a 2 Mb 2 m complex was pretreated at 100 • C for 5 minutes by mixing with 2-mercaptethanol of 5% final concentration. After transfer to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA) for 1 hour at 20 V, the membrane was incubated with Block Ace (Dainippon Pharmaceutical, Osaka, Japan) for 1 hour followed by three washes with 20 mmol/L phosphatebuffered saline (PBS) (pH 7.4) containing 0.05% Tween 20 (washing buffer). The membrane was then incubated with biotin-labeled anti-a 2 M antibody or anti-b 2 m antibody at room temperature for 1 hour. After the reaction, the membrane was washed three times with wash buffer and soaked by shaking in 5 mL of PBS containing an avidin-peroxidase-labeled biotin complex (Vectastain ABC Kit) (Vector, Burlingame, CA, USA) at room temperature for 30 minutes. Thereafter, the membrane was washed three times repeatedly with the wash buffer and reacted with nitrotetrazolium blue solution containing 0.02% hydrogen peroxide and the reduced form of nicotinamide adenine dinucleotide (NADH).
Biotin labeling of anti-a 2 M antibody. Biotinylation of anti-a 2 M polyclonal antibody (Rockland) (Gilbertsvilles, PA, USA) was performed using sulfosuccinimidyl Dbiotin (Biotin Sulfo-OSu) (Dojindo, Kumamoto, Japan). First, 1 mL of the antibody solution (0.7 mg/mL) in 0.01 mol/L hepes buffer (pH 8.5) was prepared. Next, 0.1 mL of 1 mmol/L Biotin Sulfo-OSu in distilled water was prepared and then added to the antibody solution. After complete mixing, the solution was incubated at room temperature for 4 hours. The biotinylated antibody solution was loaded into the desalting column (R1).
A coupling anti-b 2 m antibody to horseradish peroxidase. Five milligrams of horseradish peroxidase (HRP) (Toyobo, Osaka, Japan) was suspended in 1.2 mL of water and added to 0.3 mL of a freshly prepared 0.1 mol/L sodium periodate solution in 10 mmol/L sodium phosphate (pH 7.0). After the HRP solution had been incubated at room temperature for 20 minutes, it was dialyzed versus 1 mmol/L sodium acetate (pH 4.0) at 4 • C with several changes overnight. The HRP solution was removed from the dialysis tube, added to 0.5 mL of antib 2 m antibody solution, then prepared to 10 mg/mL in 20 mmol/L carbonate buffer (pH 9.0). Next, the HRP antibody solution was incubated at room temperature for 2 hours. After adding 0.1 mL of sodium borohydride (4 mg/mL in water) (Wako, Osaka, Japan) to the HRP antibody, the solution was incubated at 4 • C for 2 hours. The HRP antibody solution was then dialyzed by several changes of 10 mmol/L sodium PBS (pH 7.4).
Two-step sandwich enzyme immunoassay. Measurement of the a 2 M-b 2 m complex in serum was performed by two-step sandwich enzyme immunoassay (two-step EIA) using full automatic analysis equipment MI01 (A & T, Kanagawa, Japan). A principle of assay followed two steps: (1) a 2 M in serum was captured on reaction cup by biotin labeled anti-a 2 M antibody through antibiotin antibody, (2) b 2 m of the complex was detected by HRPlabeled anti-b 2 m antibody. In the first step, the reaction cup used for immobilizing antibiotin polyclonal antibody was coated with antibiotin polyclonal antibody (Nippon The reference line showed a good linearity from 0 to 1.0 U/mL (Fig. 2) . The intra-assay coefficient of variation was 4.67%.
Statistical analysis
Results are expressed as mean ± SD. Statistical analysis was performed using the software package, Stat View version 5.0 for Windows. Differences between the groups were compared using the Mann-Whitney U test for nonnormally distributed variables, and for normally distributed variables, compared using unpaired t test. To evaluate the relation between variables, Pearson's correlation coefficient in normally distribution, and Spearman's ranked correlation coefficient in nonnormally distribution were used. A P value less than 0.05 were considered as significant.
RESULTS
The affinity of b 2 m for a 2 M
The time course of the change in frequency of the QCM responding to 10 lL of 1 mg/mL a 2 M was recorded (Fig. 3A ). Association constants (K a ) and the maximum binding amount ( M max ) were calculated form Eadie-Hofstee plots (K a 443.27 nmol/L, M max 232.93 Hz) ( Fig. 3B) . b 2 m exhibited a very strong affinity for a 2 M in a dosedependent manner (K a 443.27 nmol/L, F max 232.93 Hz). The frequency of the QCM responding to a 2 M decreased over time, which indicated that a 2 M had significant affinity for b 2 m in a dose-dependent manner.
Serum levels of a 2 M
Serum levels of a 2 M were 151.5 ± 43.9 mg/dL in hemodialysis patients and 157.8 ± 50.3 mg/dL in prehemodialysis CRF patients. An increased level of serum a 2 M greater than maximum reference value (200 mg/dL for males and 250 mg/dL for females) could be found only 14 out of 137 cases (10.2%). Serum a 2 M values in the hemodialysis patients failed to correlate neither with the serum b 2 m values or with the a 2 M-b 2 m complex ( Fig. 4) . Serum b 2 m values showed also no correlation with the a 2 M-b 2 m complex (data not shown).
Serum levels of a 2 M-b 2 m complex
Serum levels of a 2 M-b 2 m complex could not be detected in serum from 15 normal persons, but could be detected in two out of 11 serums from the prehemodialysis CRF patients (18%), whose levels varied from 0 to 0.8 U/mL (0.09 ± 0.20 U/mL) ( Fig. 5 ). In the hemodialysis patients, the complex could be detected in 95 out of 137 serums (69.3%), which varied from 0 to 1.0 U/mL (0.20 ± 0.24 U/mL). The complex level in the hemodialysis patients was significantly higher than that in the prehemodialysis CRF patients (P = 0.013).
Correlation between the serum a 2 M-b 2 m complex levels and clinical characteristics related to hemodialysis
Serum levels of a 2 M-b 2 m complex showed a correlation with the duration of hemodialysis (q = 0.257, P = 0.043) ( Fig. 6) and an average value of the complex was significantly higher in the patients with long-term history of 12 years or more (N = 57) (0.28 ± 0.28 U/mL, 0 to 1.0 U/mL) than that in the patients with a hemodialysis history less than 12 years (N = 80) (0.15 ± 0.19 U/mL, 0 to 0.9 U/mL) (P = 0.009) ( Fig. 7) .
Furthermore, no correlation could be found between serum levels of a 2 M-b 2 m complex with the DRA scores in all hemodialysis patients, but serum complex levels were significantly higher in patients with high DRA score than that in patients with negative DRA scores (0.33 ± 0.32 U/mL vs. 0.16 ± 0.21 U/mL, P = 0.018) ( Fig. 8 ). Even so, however, the time on hemodialysis was also significantly longer in the former than in the later, 218.7 months vs. 81.3 months (P < 0.0001).
Serum complex levels in patients who underwent an operation of carpel tunnel syndrome were 0.32 ± 0.32 U/mL, which was slightly, but not significantly, higher than 0.19 ± 0.22 U/mL in patients who had not undergone an operation (P = 0.065) (data not shown).
An effect of hemodiafiltration on serum levels of the a 2 M-b 2 m complex
Serum levels of the a 2 M-b 2 m complex in 11 patients who had undergone hemodiafiltration for more than 6 months with the high-performance membrane (hemodiafiltration group) was compared with 34 patients who had no history of hemodiafiltration with the high-performance membrane (nonhemodiafiltration which were significantly lower than not only those in the nonhemodiafiltration group (from 0 to 1.0 U/mL, 0.31 ± 0.29 U/mL) (P = 0.002) ( Fig. 9 ), but also those in all hemodialysis patients included in this study (0.20 ± 0.24 U/mL) (P = 0.009). Taking into account this significant lower value of serum complex in the hemodiafiltration patients, a correlation between serum complex levels and DRA score was further studied in a patient subgroup excluding 11 hemodiafiltration patients, which 87) . In the patient with long-term history of hemodialysi, serum a 2 M-b 2 m complex levels were higher than the counter patient group (0.28 ± 0.28 U/mL vs. 0.15 ± 0.19 U/mL) (P = 0.009).
showed a significant correlation as shown in Figure 10 (q = 0.316, P = 0.0004).
DISCUSSION
The presence of a 2 M in amyloid tissue from patients with DRA was first demonstrated by Argilés et al in 1989 [3] and later corroborated by Campistol et al [4] . Thereafter, the complex formation of b 2 m with a 2 M was confirmed directly in an in vitro setting [9] and the a 2 M hypothesis for the pathogenesis of DRA was proposed [10] . Thus far, however, no report concerning a circulating complex of a 2 M-b 2 m in hemodialysis patients has been published.
At present study, we could confirm that a 2 M showed high affinity for b 2 m in vitro by QCM analysis, a new method for binding assay [13, 14] and detected b 2 m as-sociated with a 2 M (a 2 M-b 2 m complex) in serum from 95 out of 137 hemodialysis patients (69.3%). Circulating levels of a 2 M were reported to be significantly increased and had a correlation with the serum levels of b 2 m in hemodialysis patients [15, 16] . Interestingly, a significant correlation between serum levels of a 2 M and b 2 m was, however, limited to the patients with DRA in the study by Argiles et al [16] . By contrast to that study by Argilés et al, this study failed to show such correlation despite almost similar patient's background such as duration of hemodialysis. Two distinct differences could be pointed out between these two studies, one with serum levels of a 2 M and another with proportion of patients with DRA. Our study involved apparently fewer patients with increase of serum a 2 M as well as with DRA than the study of Argilés et al [16] . Not only was there no increase of serum a 2 M but also no correlation between serum levels of a 2 M and b 2 m in patients free of DRA in their study similar to our study. On the other hand, Curatola et al [15] reported merely a significant increase of serum a 2 M in hemodialysis patients. Recently, polymorphism of a 2 M gene was reported [17] , but to what extent it might be accountable for the difference in serum levels of a 2 M on hemodialysis remains unclear.
It is generally acknowledged that b 2 m is the key substance in DRA and that the development of DRA is strongly dependent on the length of time on hemodialysis, which is about 15 years on average in Japan [18] . In our study, a significant correlation was confirmed between the serum a 2 M-b 2 m complex levels and the du-ration of hemodialysis. However, we failed to find a correlation between the serum value of the a 2 M-b 2 m complex and the DRA score. In addition, patients involved in this study were extremely overbalanced by so many patients with a negative DRA score, the lower value of the serum a 2 M-b 2 m complex in the hemodiafiltration group ( Fig. 9 ), which involved more patients with high DRA scores than in the hemodialysis group and may contribute to some extent to the lack of correlation with the DRA score. Actually, a significant correlation with DRA score and a 2 M-b 2 m complex could be confirmed in patient subgroup excluding hemodiafiltration patients (P = 0.0004) ( Fig. 10 ). Although any direct inhibitory effect on protease by a 2 M must still be substantiated in DRA amyloid tissue [19] , Argilés et al [10] have given a clear indications that the a 2 M-b 2 m complex has great pathophysiologic significance in DRA and stressed the importance of an impaired catabolism of extravasated b 2 m in amyloid tissue by protection from protease [10] .
A kinetic study of b 2 m using 125 I-b 2 m suggested a progressive accumulation of b 2 m in the extravascular space along with the time on hemodialysis [20, 21] , while the serum b 2 m concentrations tended to level off [22] .
Because the bounding of the a 2 M-b 2 m complex was reported to be extremely tight, as indicated by an estimated kD of 10 −9 mol/L [10] , which was almost similar value in this study, a preformed complex is, therefore, assumed unlikely to be dissociated in the physiologic condition.
A molecular size of the complex is unlikely to be removed even by hemodiafiltration. Under such circumstance, circulating levels of the complex might be dependent on the extent by which the complex is generated.
Thus, it makes sense to assume that a lower value of serum complex in the hemodiafiltration group compared with the nonhemodiafiltration group may be due to lower b 2 m value in those patients, albeit not significant, by high shuttling effect across the vascular wall of convection flow.
A recent report by Narita et al [23] suggested the possibility of a different process from the one involving the protection from protease, which is mediated via a lowdensity lipoprotein receptor-related protein (LRP). They have shown that the amyloid b peptide-a 2 M complex is degraded by glioblastoma cells and fibroblast via LRP. Although it is not clear to what extent this process contributes to a 2 M-b 2 m catabolism, it is well-known that the involvement of activated macrophages would be ubiqui-tous in the late stages of DRA [24] [25] [26] . a 2 M is also reported to bind to LRP on macrophages. Accordingly, an analogous possibility could be suggested in catabolism of a 2 M-b 2 m complex.
As shown in a statement by Glabe [27] concerning the up-to-date report by Iwata et al [28] , the overall evidence from an investigation on the catabolic breakdown of amyloid proteins can be anticipated to provide new insights into the pathogenesis of the amyloidosis.
Of greater interest, the binding site of b 2 m to a 2 M was reported to be folded in the physiologic state [9] . The complex, therefore, may indicate the presence of an unfolded b 2 m, which suggests a conformational change in this molecule, misfolding, in vivo [29] .
Finally, as stated in a paragraph compared with the study by Argilés et al, this study involved many patients free of clinical evidences of DRA, which might enable us to undertake further study on prognostic value of a 2 Mb 2 m complex in progression of DRA.
